Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Emtricitabine

FDA-approved product (capsule, oral), marketed as Emtricitabine, Emtriva.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Emtricitabine
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • HIV infection
  • HIV-1 infection
  • Viral disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Nucleoside and nucleotide reverse transcriptase inhibitors
FDA pharmacologic class
Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor FDA label ↗
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J05AF09

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA45.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli25.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae33.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis50.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Emtricitabine in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.0 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.6 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-6.3 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-5.9 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Emtricitabine with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062)

    NCT07266831 · start 2025-12-18

    Registered record
    Registry ID
    NCT07266831
    Conditions
    Human Immunodeficiency Virus Type 1 (HIV-1) Infection
    Interventions
    ISL; ULO; BIC/FTC/TAF; Placebo for BIC/FTC/TAF; Placebo to ISL/ULO; ISL/ULO
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Recruiting
    Start
    2025-12-18
    Completion
    2031-12-18
    Enrolment
    570

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHuman Immunodeficiency Virus Type 1 (HIV-1) Infection
    InterventionISL; ULO; BIC/FTC/TAF; Placebo for BIC/FTC/TAF +2 more
    PhasePhase 2 / Phase 3
    Registry statusRecruiting

  • Safety, Tolerability, and Efficacy of a Dose Reduction Strategy Based on Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV-infected Adults

    NCT05602506 · start 2022-11-15

    Registered record
    Registry ID
    NCT05602506
    Conditions
    HIV Infections
    Interventions
    Biktarvy 50 mg/200 mg/25 mg film-coated tablets
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2022-11-15
    Completion
    2024-06-05
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionBiktarvy 50 mg/200 mg/25 mg film-coated tablets
    PhasePhase 4
    Registry statusCompleted

  • Doravirine and Weight Gain in Antiretroviral Naive

    NCT05457530 · start 2022-08-01

    Registered record
    Registry ID
    NCT05457530
    Conditions
    Body Weight Changes; Human Immunodeficiency Virus; ART; Obesity; Minority Health; BMD; Metabolic Syndrome; Fasting
    Interventions
    DOR/3TC/TDF; DOR + FTC/TAF; BIC/FTC/TAF
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Withdrawn
    Start
    2022-08-01
    Completion
    2023-05-03
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBody Weight Changes; Human Immunodeficiency Virus; ART; Obesity +4 more
    InterventionDOR/3TC/TDF; DOR + FTC/TAF; BIC/FTC/TAF
    PhasePhase 3
    Registry statusWithdrawn

  • Switching From TDF-based Antiretroviral Therapy Regimens to B/F/TAF in Virally Suppressed Adults With HIV-1 Infection

    NCT05122754 · start 2021-12-08

    Registered record
    Registry ID
    NCT05122754
    Conditions
    HIV-1-infection
    Interventions
    B/F/TAF; TDF-based triple ART regimen switching to B/F/TAF
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2021-12-08
    Completion
    2024-04-28
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-1-infection
    InterventionB/F/TAF; TDF-based triple ART regimen switching to B/F/TAF
    PhasePhase 4
    Registry statusUnknown

  • Biktarvy in Treatment-Naïve Late Presenters With HIV-1 Infection

    NCT04296695 · start 2021-07-14

    Registered record
    Registry ID
    NCT04296695
    Conditions
    HIV-1-infection
    Interventions
    B/F/TAF; TDF/3TC/EFV
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2021-07-14
    Completion
    2025-06-06
    Enrolment
    202

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-1-infection
    InterventionB/F/TAF; TDF/3TC/EFV
    PhasePhase 4
    Registry statusCompleted

  • Study of Lenacapavir for HIV Pre-Exposure Prophylaxis in People Who Are at Risk for HIV Infection

    NCT04925752 · start 2021-06-28

    Registered record
    Registry ID
    NCT04925752
    Conditions
    Pre-Exposure Prophylaxis of HIV Infection
    Interventions
    Oral Lenacapavir (LEN); F/TDF; Sub-cutaneous (SC) Lenacapavir (LEN); Placebo SC LEN; PTM F/TDF; PTM Oral LEN; F/TAF (for US participants only)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2021-06-28
    Completion
    2028-08
    Enrolment
    3,292

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPre-Exposure Prophylaxis of HIV Infection
    InterventionOral Lenacapavir (LEN); F/TDF; Sub-cutaneous (SC) Lenacapavir (LEN); Placebo SC LEN +3 more
    PhasePhase 3
    Registry statusActive not recruiting

  • Pre-Exposure Prophylaxis (PrEP)- Gender Affirming Hormone Therapy (GAHT) Interactions in TGW

    NCT04760691 · start 2021-03-01

    Registered record
    Registry ID
    NCT04760691
    Conditions
    HIV; Prophylaxis; Transgender
    Interventions
    Truvada alone; Truvada plus Leuprolide 11.25mg intramuscular injection; Truvada plus Estradiol 1 mg; Truvada plus Estradiol 6 mg; Estradiol 6 mg alone
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2021-03-01
    Completion
    2025-03-24
    Enrolment
    13

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV; Prophylaxis; Transgender
    InterventionTruvada alone; Truvada plus Leuprolide 11.25mg intramuscular injection; Truvada plus Estradiol 1 mg; Truvada plus Estradiol 6 mg +1 more
    PhasePhase 1
    Registry statusCompleted

  • Inflammation and Co-Infections in D²EFT

    NCT04183738 · start 2021-02-01

    Registered record
    Registry ID
    NCT04183738
    Conditions
    HIV-infection/Aids; Human Herpesvirus 4 Infections; Cytomegalovirus Infections; Human Herpesvirus 8 Infection; Human Papilloma Virus
    Interventions
    NRTIs; Darunavir; Ritonavir; Dolutegravir
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Withdrawn
    Start
    2021-02-01
    Completion
    2022-12-19
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-infection/Aids; Human Herpesvirus 4 Infections; Cytomegalovirus Infections; Human Herpesvirus 8 Infection +1 more
    InterventionNRTIs; Darunavir; Ritonavir; Dolutegravir
    PhasePhase 4
    Registry statusWithdrawn

  • ANCHORS Alcohol & Sexual Health Study: UH3 Project

    NCT04331704 · start 2021-01-12

    Registered record
    Registry ID
    NCT04331704
    Conditions
    Alcohol Use, Unspecified; Substance Use; Sex Behavior
    Interventions
    PrEP acronym (pre-exposure prophylaxis); Initial Web Survey; Interactive Voice Response (IVR) monitoring; Educational material on alcohol and sexual health behavior; Interactive Voice Response (IVR) assessment with personalized information; Personalized information based on web-based survey responses & standardized information
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2021-01-12
    Completion
    2026-06-30
    Enrolment
    88

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAlcohol Use, Unspecified; Substance Use; Sex Behavior
    InterventionPrEP acronym (pre-exposure prophylaxis); Initial Web Survey; Interactive Voice Response (IVR) monitoring; Educational material on alcohol and sexual health behavior +2 more
    PhasePhase 4
    Registry statusRecruiting

  • Effect of Tenofovir/Emtricitabine in Patients Recently Infected With SARS-COV2 (Covid-19) Discharged Home

    NCT04685512 · start 2020-11-18

    Registered record
    Registry ID
    NCT04685512
    Conditions
    Covid19
    Interventions
    tenofovir disoproxil and emtricitabine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2020-11-18
    Completion
    2021-05-01
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCovid19
    Interventiontenofovir disoproxil and emtricitabine
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Efficacy of BIC/F/TAF Versus Standard of Care in the Treatment of New HIV Infection Diagnoses in the Context of 'Test and Treat'

    NCT04653194 · start 2020-09-30

    Registered record
    Registry ID
    NCT04653194
    Conditions
    Human Immunodeficiency Virus
    Interventions
    Biktarvy; Symtuza
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2020-09-30
    Completion
    2023-07-31
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHuman Immunodeficiency Virus
    InterventionBiktarvy; Symtuza
    PhasePhase 3
    Registry statusCompleted

  • Safety, Tolerability and Acceptability of Long-Acting Cabotegravir (CAB LA) for the Prevention of HIV Among Adolescent Males

    NCT04692077 · start 2020-02-19

    Registered record
    Registry ID
    NCT04692077
    Conditions
    HIV Infections
    Interventions
    Cabotegravir (CAB) tablet; CAB LA; Tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) tablet
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2020-02-19
    Completion
    2023-07-07
    Enrolment
    9

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionCabotegravir (CAB) tablet; CAB LA; Tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) tablet
    PhasePhase 2
    Registry statusCompleted

  • Seville Cohort of People at Substantial Risk for HIV Infection on Pre-exposure Prophylaxis

    NCT05492565 · start 2020-01-01

    Registered record
    Registry ID
    NCT05492565
    Conditions
    HIV Infection Primary; Hepatitis, Viral, Human; Sexually Transmitted Infections, Excluding HIV and Hepatitis
    Interventions
    Tenofovir Disoproxil Fumarate 300 MG Oral Tablet
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Enrolling by invitation
    Start
    2020-01-01
    Completion
    2030-12-31
    Enrolment
    500

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infection Primary; Hepatitis, Viral, Human; Sexually Transmitted Infections, Excluding HIV and Hepatitis
    InterventionTenofovir Disoproxil Fumarate 300 MG Oral Tablet
    PhaseNot recorded
    Registry statusEnrolling by invitation

  • Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide as Maintenance Treatment for HIV/HBV-coinfection

    NCT03425994 · start 2018-02-06

    Registered record
    Registry ID
    NCT03425994
    Conditions
    Chronic Hepatitis B in HIV Patient; Kidney Injury; Bone Diseases
    Interventions
    Elvitegravir/Cobicistat/Emtricitabine
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2018-02-06
    Completion
    2019-10-11
    Enrolment
    275

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Hepatitis B in HIV Patient; Kidney Injury; Bone Diseases
    InterventionElvitegravir/Cobicistat/Emtricitabine
    PhaseNot recorded
    Registry statusUnknown

  • A Pharmacokinetic Evaluation of Tenofovir/Emtricitabine as HIV Pre-Exposure Prophylaxis in Transgender Women

    NCT03270969 · start 2018-01-05

    Registered record
    Registry ID
    NCT03270969
    Conditions
    HIV Prevention
    Interventions
    Tenofovir Disoproxil Fumarate/Emtricitabine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2018-01-05
    Completion
    2018-09-10
    Enrolment
    15

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Prevention
    InterventionTenofovir Disoproxil Fumarate/Emtricitabine
    PhasePhase 1
    Registry statusCompleted